Reconstitution chart: 10 mg vial
| BAC water added | Concentration | Draw for 2.5 mg dose | Draw for 5 mg dose |
|---|---|---|---|
| 1 mL | 10,000 mcg/mL | 25 units | 50 units |
| 1.5 mL | 6,667 mcg/mL | 37.5 units | 75 units |
| 2 mL | 5,000 mcg/mL | 50 units | 100 units |
Draws are U-100 insulin syringe units (100 units = 1 mL). Formula: dose in mcg ÷ (vial mcg ÷ water mL) × 100. The calculator above handles any other combination.
About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist from Eli Lilly, sold as Mounjaro for type 2 diabetes and Zepbound for weight management. Both brand products are FDA approved and come in pre-filled pens and single-dose vials. The reconstitution math on this page applies to compounded and research-grade tirzepatide, which ships as unmarked lyophilized powder.
The approved titration ladder starts at 2.5 mg once weekly and moves up in 2.5 mg steps, with at least four weeks at each level, to a maximum of 15 mg. Notice the scale: tirzepatide doses are written in whole milligrams, ten times the size of most other injectable peptides, which are dosed in micrograms. That scale difference is why unit mixups with tirzepatide are so costly. If you enter a tirzepatide dose and the warning about units fires, stop and re-read your protocol before injecting anything.
Tirzepatide has a half-life of about 5 days, supporting the once-weekly schedule. Gray-market vials commonly run from 5 mg up to 30 mg or more. The bigger the vial, the more water it takes to keep your draw on a readable part of the syringe, and the more doses one vial holds. The doses-per-vial figure in the result card does that supply math for you.
Quick facts
- Status: FDA approved as Mounjaro and Zepbound (compounded and research vials are a separate, unapproved supply chain)
- Half-life: about 5 days, injected once weekly
- Approved ladder: 2.5 mg weekly, stepping up 2.5 mg at a time to 15 mg max
- Common gray-market vial sizes: 5, 10, 15, and 30 mg